Arrowhead Pharmaceuticals and Novartis have entered into a global licensing and collaboration agreement for ARO-SNCA, a preclinical stage siRNA therapy for synucleinopathies.
Arrowhead will receive an upfront payment of $200 million and is eligible for up to $2 billion in potential milestone payments and royalties on commercial sales.
Novartis gains an exclusive worldwide license to ARO-SNCA and other collaboration targets using Arrowhead's TRiMTM platform for subcutaneous delivery to the CNS.
Financial Terms
Upon closing, Arrowhead will receive $200 million upfront, up to $2 billion in potential milestone payments, and tiered royalties on commercial sales.
Agreement Details
Novartis gains exclusive worldwide rights to ARO-SNCA and select additional collaboration targets leveraging Arrowhead's TRiMTM platform.
Development Partnership
Arrowhead will conduct preclinical research for Novartis-licensed programs with Novartis assuming control over development, manufacturing, and commercialization.
- The agreement showcases Arrowhead's TRiMTM platform's potential in delivering RNA medicines to the brain for neurodegenerative diseases like Parkinson's Disease.
- Novartis aims to transform patient lives by advancing treatments that target core drivers in Parkinson's and neurodegenerative diseases.
The collaboration between Arrowhead Pharmaceuticals and Novartis represents a significant advancement in the treatment of neurodegenerative diseases, particularly Parkinson's Disease. The partnership holds promise for groundbreaking therapies and meaningful impacts on patient care.